Cargando…

Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial

BACKGROUND: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been link...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaughran, Fiona, Stringer, Dominic, Berk, Michael, Smith, Shubulade, Taylor, David, Whiskey, Eromona, Landau, Sabine, Murray, Robin, McGuire, Philip, Gardner-Sood, Poonam, Wojewodka, Gabriella, Ciufolini, Simone, Jordan, Harriet, Clarke, Jessie, Allen, Lauren, Krivoy, Amir, Stubbs, Brendon, Lowe, Philippa, Arbuthnott, Maurice, Rathod, Shanaya, Boardman, Andrew, Firdosi, Mudasir, McGrath, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945550/
https://www.ncbi.nlm.nih.gov/pubmed/31907006
http://dx.doi.org/10.1186/s13063-019-3758-9
_version_ 1783485200649420800
author Gaughran, Fiona
Stringer, Dominic
Berk, Michael
Smith, Shubulade
Taylor, David
Whiskey, Eromona
Landau, Sabine
Murray, Robin
McGuire, Philip
Gardner-Sood, Poonam
Wojewodka, Gabriella
Ciufolini, Simone
Jordan, Harriet
Clarke, Jessie
Allen, Lauren
Krivoy, Amir
Stubbs, Brendon
Lowe, Philippa
Arbuthnott, Maurice
Rathod, Shanaya
Boardman, Andrew
Firdosi, Mudasir
McGrath, John J.
author_facet Gaughran, Fiona
Stringer, Dominic
Berk, Michael
Smith, Shubulade
Taylor, David
Whiskey, Eromona
Landau, Sabine
Murray, Robin
McGuire, Philip
Gardner-Sood, Poonam
Wojewodka, Gabriella
Ciufolini, Simone
Jordan, Harriet
Clarke, Jessie
Allen, Lauren
Krivoy, Amir
Stubbs, Brendon
Lowe, Philippa
Arbuthnott, Maurice
Rathod, Shanaya
Boardman, Andrew
Firdosi, Mudasir
McGrath, John J.
author_sort Gaughran, Fiona
collection PubMed
description BACKGROUND: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been linked to a later increased risk of schizophrenia and psychotic-like experiences. This trial aims to examine the effect of high-dose vitamin D supplementation on outcomes in early psychosis. We hypothesise that vitamin D supplementation will be associated with better mental health outcomes. METHODS/DESIGN: The DFEND study is a multicentre double-blind placebo-controlled parallel-group trial of vitamin D supplementation in people with early psychosis. Patients with an ICD-10 diagnosis of functional psychosis will be randomised in a 1:1 ratio to receive either 120,000 IU/month of vitamin D (cholecalciferol) or a matched placebo for 6 months. The primary outcome is the total Positive and Negative Syndrome Scale (PANSS) score at the 6-month follow-up for all patients. Secondary outcomes include assessment of mood (Calgary Depression Scale), general function (Global Assessment of Functioning), cardiovascular risk (body mass index, waist circumference, C-reactive protein, cholesterol and HbA1c) and vitamin D levels at the 6-month follow-up. Additionally, 3- and 6-month total PANSS scores will be analysed for those with inadequate vitamin D levels at the baseline. DISCUSSION: The DFEND study is the first trial to examine whether vitamin D supplementation in early psychosis is associated with better mental health outcomes. The findings of this study may help to resolve the clinical equipoise regarding the benefits and cost-effectiveness of routine vitamin D supplementation in people with psychosis. TRIAL REGISTRATION: ISRCTN, ISRCTN12424842. Registered on 25 February 2015.
format Online
Article
Text
id pubmed-6945550
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69455502020-01-07 Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial Gaughran, Fiona Stringer, Dominic Berk, Michael Smith, Shubulade Taylor, David Whiskey, Eromona Landau, Sabine Murray, Robin McGuire, Philip Gardner-Sood, Poonam Wojewodka, Gabriella Ciufolini, Simone Jordan, Harriet Clarke, Jessie Allen, Lauren Krivoy, Amir Stubbs, Brendon Lowe, Philippa Arbuthnott, Maurice Rathod, Shanaya Boardman, Andrew Firdosi, Mudasir McGrath, John J. Trials Study Protocol BACKGROUND: People experiencing their first episode of psychosis are often deficient in vitamin D. Observational studies have reported an association between low vitamin D concentrations and poorer subsequent health outcomes in psychosis. A vitamin D deficiency in neonates and children has been linked to a later increased risk of schizophrenia and psychotic-like experiences. This trial aims to examine the effect of high-dose vitamin D supplementation on outcomes in early psychosis. We hypothesise that vitamin D supplementation will be associated with better mental health outcomes. METHODS/DESIGN: The DFEND study is a multicentre double-blind placebo-controlled parallel-group trial of vitamin D supplementation in people with early psychosis. Patients with an ICD-10 diagnosis of functional psychosis will be randomised in a 1:1 ratio to receive either 120,000 IU/month of vitamin D (cholecalciferol) or a matched placebo for 6 months. The primary outcome is the total Positive and Negative Syndrome Scale (PANSS) score at the 6-month follow-up for all patients. Secondary outcomes include assessment of mood (Calgary Depression Scale), general function (Global Assessment of Functioning), cardiovascular risk (body mass index, waist circumference, C-reactive protein, cholesterol and HbA1c) and vitamin D levels at the 6-month follow-up. Additionally, 3- and 6-month total PANSS scores will be analysed for those with inadequate vitamin D levels at the baseline. DISCUSSION: The DFEND study is the first trial to examine whether vitamin D supplementation in early psychosis is associated with better mental health outcomes. The findings of this study may help to resolve the clinical equipoise regarding the benefits and cost-effectiveness of routine vitamin D supplementation in people with psychosis. TRIAL REGISTRATION: ISRCTN, ISRCTN12424842. Registered on 25 February 2015. BioMed Central 2020-01-06 /pmc/articles/PMC6945550/ /pubmed/31907006 http://dx.doi.org/10.1186/s13063-019-3758-9 Text en © The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Gaughran, Fiona
Stringer, Dominic
Berk, Michael
Smith, Shubulade
Taylor, David
Whiskey, Eromona
Landau, Sabine
Murray, Robin
McGuire, Philip
Gardner-Sood, Poonam
Wojewodka, Gabriella
Ciufolini, Simone
Jordan, Harriet
Clarke, Jessie
Allen, Lauren
Krivoy, Amir
Stubbs, Brendon
Lowe, Philippa
Arbuthnott, Maurice
Rathod, Shanaya
Boardman, Andrew
Firdosi, Mudasir
McGrath, John J.
Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
title Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
title_full Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
title_fullStr Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
title_full_unstemmed Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
title_short Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
title_sort vitamin d supplementation compared to placebo in people with first episode psychosis - neuroprotection design (dfend): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945550/
https://www.ncbi.nlm.nih.gov/pubmed/31907006
http://dx.doi.org/10.1186/s13063-019-3758-9
work_keys_str_mv AT gaughranfiona vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT stringerdominic vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT berkmichael vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT smithshubulade vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT taylordavid vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT whiskeyeromona vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT landausabine vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT murrayrobin vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT mcguirephilip vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT gardnersoodpoonam vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT wojewodkagabriella vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT ciufolinisimone vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT jordanharriet vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT clarkejessie vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT allenlauren vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT krivoyamir vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT stubbsbrendon vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT lowephilippa vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT arbuthnottmaurice vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT rathodshanaya vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT boardmanandrew vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT firdosimudasir vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial
AT mcgrathjohnj vitamindsupplementationcomparedtoplaceboinpeoplewithfirstepisodepsychosisneuroprotectiondesigndfendaprotocolforarandomiseddoubleblindplacebocontrolledparallelgrouptrial